Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Personalised treatment for lung cancer

ELCC 2010

28 Apr - 1 May 2010

Published: 7 Jun 2010

Views: 8921

Rating:

Save

Prof Paul Bunn - University of Colorado, Denver

Prof Paul Bunn speaks at the 2010 ELCC conference about developments in lung cancer treatments. Prof Bunn discusses the importance of oestrogen receptors, the need for tumour biopsies in order to provide personalised treatment, developments in the identification of mutations and providing mutation specific medication.

Click here to watch an interview with Prof Bunn discussing first line therapy for lung cancer at AACR 2009.

Related Videos

Avelumab combined with regorafenib shows improved outcome in solid tumours with...

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC ( Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for...

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )

EGFR mutations in NSCLC - from biomarker to treatment selections in second line

Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo

EGFR mutations in NSCLC - from biomarker to treatment selections in second line ( Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo )

Topics under discussion at the WCLC 2022 presidential symposium

Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain

Topics under discussion at the WCLC 2022 presidential symposium ( Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )

ASCO 2022: Latest in EGFR positive NSCLC

Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip

ASCO 2022: Latest in EGFR positive NSCLC ( Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip )

More from ecancer